FOLFOX4化疗方案联合康艾注射液对原发性肝癌患者血清AFP、CEA和CA19-9水平及免疫功能的影响

Effects of FOLFOX4 Chemotherapy Combined with Kang’ai Injection on Serum AFP,CEA and CA19-9 Levels and Immune Function in Patients with Primary Hepatic Carcinoma

目的:探讨FOLFOX4化疗方案联合康艾注射液对原发性肝癌(PHC)患者血清甲胎蛋白(AFP)、癌胚抗原(CEA)和糖类抗原19-9(CA19-9)水平及免疫功能的影响。方法:选择2019年6月-2021年5月于江西中医药大学附属医院治疗的86例PHC患者,按随机数字表法将其分为两组,各43例。对照组采用FOLFOX4化疗方案治疗,观察组采用FOLFOX4化疗方案、康艾注射液治疗,两组均治疗3个疗程。比较两组肿瘤标志物、免疫功能及不良反应。结果:治疗3个疗程后,两组AFP、CEA及CA19-9水平均低于治疗前,且观察组均低于对照组,差异均有统计学意义(P<0.05)。治疗3个疗程后,对照组CD4^(+)、CD4^(+)/CD8^(+)均低于治疗前,CD8^(+)高于治疗前,观察组CD4^(+)、CD4^(+)/CD8^(+)均高于对照组,CD8^(+)低于对照组,差异均有统计学意义(P<0.05);观察组治疗3个疗程后CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)与治疗前比较,差异均无统计学意义(P>0.05)。观察组血小板减少、白细胞减少、胃肠道反应发生率均低于对照组,差异均有统计学意义(P<0.05)。结论:PHC患者采用FOLFOX4化疗方案联合康艾注射液治疗是安全可行的,有利于降低血清AFP、CEA及CA19-9水平,减轻单纯化疗治疗对患者免疫功能的损伤,有利于控制病情进展,并可减少不良反应的发生。

Objective:To investigate the effects of FOLFOX4 chemotherapy combined with Kang’ai Injection on serum alpha fetoprotein(AFP),carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)and immune function in patients with primary hepatic carcinoma(PHC).Method:A total of 86 PHC patients treated in Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine from June 2019 to May 2021 were selected and divided into two groups according to random number table method,43 cases in each group.The control group was treated with FOLFOX4 chemotherapy regimen,and the observation group was treated with FOLFOX4 chemotherapy regimen and Kang’ai Injection,two groups were treated for 3 courses.Tumor markers,immune function and adverse reactions were compared between two groups.Result:After 3 courses of treatment,the levels of AFP,CEA and CA19-9 in two groups were lower than before,and the observation group were lower than the control group,the differences were statistically significant(P<0.05).After 3 courses of treatment,the CD4^(+)and CD4^(+)/CD8^(+)in the control group were lower than those before treatment,while CD8^(+)was higher than that before treatment,and the CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,while the CD8^(+)was lower than that in the control group,the differences were statistically significant(P<0.05).There were no significant differences in the CD4^(+),CD8^(+),CD4^(+)/CD8^(+)in the observation group after 3 courses of treatment were compared with those before treatment(P>0.05).The incidences of thrombocytopenia,leukopenia and gastrointestinal reactions in the observation group were lower than those in the control group,with statistical significance(P<0.05).Conclusion:FOLFOX4 chemotherapy combined with Kang’ai Injection is safe and feasible for PHC patients,which is beneficial to reduce the levels of AFP,CEA and CA19-9 in serum,reduce the damage of immune function caused by chemotherapy alone,control the progression of the disease and reduce the occurrence of adverse reactions.